[go: up one dir, main page]

WO2017042837A3 - Stable crystalline form of regadenoson - Google Patents

Stable crystalline form of regadenoson Download PDF

Info

Publication number
WO2017042837A3
WO2017042837A3 PCT/IN2016/050303 IN2016050303W WO2017042837A3 WO 2017042837 A3 WO2017042837 A3 WO 2017042837A3 IN 2016050303 W IN2016050303 W IN 2016050303W WO 2017042837 A3 WO2017042837 A3 WO 2017042837A3
Authority
WO
WIPO (PCT)
Prior art keywords
regadenoson
crystalline form
stable crystalline
degrees
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2016/050303
Other languages
French (fr)
Other versions
WO2017042837A2 (en
Inventor
Rajamannar Thennati
Shriprakash Dhar DWIVEDI
Arunkumar Gulabsingh Yadav
Nischalkumar Vinodbhai Patel
Sunil Rajaram KARANKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Priority to US15/758,971 priority Critical patent/US20180208622A1/en
Publication of WO2017042837A2 publication Critical patent/WO2017042837A2/en
Anticipated expiration legal-status Critical
Publication of WO2017042837A3 publication Critical patent/WO2017042837A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides crystalline Form S of regadenoson which is substantially free of residual organic solvent and having an X-ray powder diffraction pattern comprising characteristic peak at 10.3, 10.8, 19.0, 21.6 and 25.5 ± 0.2 degrees 2θ.
PCT/IN2016/050303 2015-09-11 2016-09-10 Stable crystalline form of regadenoson Ceased WO2017042837A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/758,971 US20180208622A1 (en) 2015-09-11 2016-09-10 Stable crystalline form of regadenoson

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3485/MUM/2015 2015-09-11
IN3485MU2015 2015-09-11

Publications (2)

Publication Number Publication Date
WO2017042837A2 WO2017042837A2 (en) 2017-03-16
WO2017042837A3 true WO2017042837A3 (en) 2018-08-23

Family

ID=58239242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2016/050303 Ceased WO2017042837A2 (en) 2015-09-11 2016-09-10 Stable crystalline form of regadenoson

Country Status (2)

Country Link
US (1) US20180208622A1 (en)
WO (1) WO2017042837A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016126734A1 (en) * 2015-02-06 2016-08-11 Apicore Us Llc Process of making regadenoson and novel polymorph thereof
WO2019191389A1 (en) 2018-03-29 2019-10-03 Johnson Matthey Public Limited Company Solid-state forms of regadenoson, their use and preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149196A1 (en) * 2011-04-27 2012-11-01 Reliable Biopharmaceutical Corporation Improved processes for the preparation of regadenoson and a new crystalline form thereof
EP2789624A1 (en) * 2013-04-11 2014-10-15 Euticals S.P.A. Stable solid forms of regadenoson

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012369A (en) * 2007-05-17 2009-12-01 Cv Therapeutics Inc Process for preparing an a2a-adenosine receptor agonist and its polymorphs.
CA2753599C (en) * 2009-02-26 2017-03-14 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
CZ305213B6 (en) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorph E, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine and process for its preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149196A1 (en) * 2011-04-27 2012-11-01 Reliable Biopharmaceutical Corporation Improved processes for the preparation of regadenoson and a new crystalline form thereof
EP2789624A1 (en) * 2013-04-11 2014-10-15 Euticals S.P.A. Stable solid forms of regadenoson

Also Published As

Publication number Publication date
WO2017042837A2 (en) 2017-03-16
US20180208622A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
IL271962A (en) Preparation of substituted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles
PL3668937T3 (en) Compositions and uses of z-1-chloro-2,3,3,3-tetrafluoroprop-1-ene
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
EP3481402A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2016011222A3 (en) Circular polynucleotides
WO2017059059A8 (en) Crystalline forms of a hepatitis b antiviral agent
EP3484504A4 (en) Compounds, compositions, and methods for the treatment of disease
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
EP3623957A4 (en) Generation of point of interest copy
WO2018006074A3 (en) Compounds and methods for modulating rna function
WO2015195656A3 (en) Synthesis of polycyclic-carbamoylpyridone compounds
IL271399A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3574634A4 (en) Interference generation
EP3688590A4 (en) Policy based persistence
IL273896A (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
EP3574081A4 (en) Methods and microorganisms for making 2,3-butanediol and derivatives thereof from c1 carbons
HK1255104A1 (en) Amorphous onapristone compositions and methods of making the same
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
WO2017042837A3 (en) Stable crystalline form of regadenoson
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
EP3607144A4 (en) Locking of points
EP3576769A4 (en) Compounds, compositions and uses thereof for improvement of bone disorders
WO2016086022A3 (en) Heteroaromatic imidazolyl compounds and methods for treating cancer
WO2019014286A3 (en) Improved processes for the preparation of guadecitabine and intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16843860

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15758971

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16843860

Country of ref document: EP

Kind code of ref document: A2